M Holdings Securities Inc. Makes New $691,000 Investment in Gilead Sciences, Inc. $GILD

M Holdings Securities Inc. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, Holdings Channel.com reports. The firm bought 4,348 shares of the biopharmaceutical company’s stock, valued at approximately $691,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Gilead Sciences by 20.5% in the 3rd quarter. Brighton Jones LLC now owns 22,640 shares of the biopharmaceutical company’s stock valued at $3,374,000 after purchasing an additional 3,844 shares in the last quarter. Candriam S.C.A. raised its stake in shares of Gilead Sciences by 4.3% during the 3rd quarter. Candriam S.C.A. now owns 1,242,210 shares of the biopharmaceutical company’s stock worth $185,828,000 after buying an additional 50,830 shares in the last quarter. American State Bank Iowa raised its stake in shares of Gilead Sciences by 6.1% during the 3rd quarter. American State Bank Iowa now owns 11,430 shares of the biopharmaceutical company’s stock worth $1,704,000 after buying an additional 655 shares in the last quarter. Uhlmann Price Securities LLC lifted its holdings in shares of Gilead Sciences by 4.9% in the 3rd quarter. Uhlmann Price Securities LLC now owns 4,189 shares of the biopharmaceutical company’s stock valued at $624,000 after buying an additional 195 shares during the period. Finally, Ethic Inc. lifted its holdings in shares of Gilead Sciences by 10.3% in the 3rd quarter. Ethic Inc. now owns 103,445 shares of the biopharmaceutical company’s stock valued at $15,418,000 after buying an additional 9,688 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GILD shares. Jefferies Financial Group set a $196.00 price target on Gilead Sciences in a research note on Wednesday, November 4th. Citigroup increased their price objective on Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Bank of America increased their price objective on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Cantor Fitzgerald raised their target price on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, Sanford C. Bernstein restated an “outperform” rating and set a $175.00 target price on shares of Gilead Sciences in a research report on Monday, November 2nd. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $170.15.

Gilead Sciences Trading Up 0.9%

Shares of GILD opened at $170.87 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $176.58. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84. The firm has a market capitalization of $211.94 billion, a P/E ratio of -54.07 and a beta of 0.35. The firm’s 50-day moving average is $154.00 and its two-hundred day moving average is $141.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period last year, the firm earned $2.47 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post -1.07 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the sale, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 102,619 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total value of $17,974,744.04. Following the completion of the sale, the chief executive officer directly owned 551,683 shares in the company, valued at $96,632,794.28. This trade represents a 15.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 242,709 shares of company stock worth $39,503,427 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Recent coverage highlights improving growth across Gilead’s business and strong recent results. Its latest reported quarter beat consensus on both earnings and revenue, with revenue up 6.8% year over year. This supports the positive investment case behind the stock’s advance toward a 52-week high. Article: Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
• Positive Sentiment: Analysts have recently raised price targets, including JPMorgan and Wells Fargo to $190, and maintained positive ratings—potential support for investor sentiment. Gilead Sciences analyst and stock information
• Neutral Sentiment: Gilead partner Xilio Therapeutics said it expects to deliver an option data package for its investigational cancer drug efarindodekin alfa to Gilead in the first half of 2027. Any value to Gilead depends on future data and potential payments; the update does not establish a near-term financial benefit. Xilio Therapeutics pipeline update
• Negative Sentiment: An executive vice president sold 3,399 shares, reducing his holdings by about 39%. The sale was made under a pre-arranged trading plan, which may limit its significance as a signal about the company’s outlook. Gilead Sciences insider-trading report
• Negative Sentiment: Vir, a competitor in hepatitis D, reported positive results for its experimental treatment. The news could raise competitive concerns, though the supplied report does not indicate an immediate impact on Gilead’s business. Vir rival advances hepatitis D treatment

Gilead Sciences Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.